Xie Bai San (Drain the White Powder)

Actions

Indications

Western Uses:

• What is Xie Bai San used for in modern practice?

  In modern practice Xie Bai San is referenced, in its traditional Lung-heat role, for pediatric cough and wheezing conditions such as bronchitis, whooping cough, and pneumonia in children — contexts where Western medicine recognizes a productive or spasmodic cough with low-grade fever. It originates from a Song-dynasty pediatric text (Qian Yi’s Xiao’er Yao Zheng Zhi Jue) and has long been associated with children’s respiratory complaints, though it is also used in adults with the matching Lung-heat pattern.

  These biomedical correlates are offered as a reference to the formula’s traditional use, not as a claim that it treats any disease. Contemporary study is mostly preclinical network-pharmacology and pharmacokinetic work (see research). Any use for a diagnosed respiratory condition belongs with a qualified practitioner and appropriate medical care.

  Source: traditional-use correlates summarized from Bensky & Barolet, Formulas & Strategies, and Chen & Chen, Chinese Herbal Formulas and Applications (formula origin and pediatric association); reference only, not a treatment claim.

Originally Appeared In:

• Craft of Medicinal Treatment for Childhood Disease Patterns (Xiao Er Yao Zheng Zhi Jue)

Notes:

• How is Xie Bai San different from Ma Xing Shi Gan Tang and other Lung-heat formulas?

  Xie Bai San is a milder formula for smoldering, lingering Lung heat, whereas Ma Xing Shi Gan Tang is a stronger formula for acute Lung heat with wheezing from an unresolved external invasion. Choosing between them depends on how the heat arose and how intense the presentation is.

  • vs Ma Xing Shi Gan Tang: Ma Xing Shi Gan Tang combines Ma Huang, Xing Ren, Shi Gao, and Gan Cao for more forceful, acute Lung heat with sweating, higher fever, and more severe wheezing following an external pathogen; Xie Bai San is gentler, for heat that has smoldered rather than surged, without a strong exterior component.
  • vs Xie Huang San: a related "draining" formula from the same source text, but targeting Spleen/Stomach heat (mouth sores, bad breath) rather than Lung heat and wheezing.
  • Key modifications: add Huang Qin and Zhi Mu for more pronounced heat; add Di Long, Chuan Bei Mu, or Sang Ye for stronger phlegm-heat wheezing; add Mai Men Dong or Sha Shen when heat has also damaged Lung yin/fluids (dry cough, dry mouth).

  Source: Bensky & Barolet, Formulas & Strategies (formula comparisons and standard modifications).

Clinical Studies & Research:

• Is there modern research on Xie Bai San?

  Yes, but it is largely preclinical — network-pharmacology and pharmacokinetic studies on the whole formula, plus compound-level work on its individual herbs. A network-pharmacology study of Xiebai San (Xie Bai San) for pediatric pneumonia identified 120 active ingredients (quercetin and kaempferol prominent among them) and 128 potential targets, and found the formula suppressed LPS-induced NF-κB p65 activation and the pro-inflammatory cytokines IL-6 and IL-1β in experimental validation. Separate pharmacokinetic work found that decocting the four herbs together causes the formula’s active compounds to self-assemble into natural nanoparticles (~105 nm), which enhanced their oral absorption and blood levels in rats compared to the free compounds — a possible modern explanation for why the whole decoction (rice included) is prepared as a unit rather than as separate extracts.

  • Pediatric pneumonia mechanism (network pharmacology + in vitro validation): Xiebai San suppressed NF-κB p65 activation and IL-6/IL-1β production induced by LPS (PMID 35237157).
  • Formula-level pharmacokinetics (nanoparticle self-assembly): whole-decoction preparation of Xie-Bai-San forms self-assembled nanoparticles (~104.5 nm) that raised oral bioavailability of key active compounds in rats versus the compounds alone (PMID 38617795).
  • Di Gu Pi (Lycium chinense root bark), compound-level: nine compounds isolated from the root bark showed anti-inflammatory activity, with several exceeding the curcumin positive control in vitro (PMID 28752035).

  Sources: PubMed 35237157; PubMed 38617795; PubMed 28752035. Research context, not a therapeutic claim; direct clinical trial evidence in humans remains limited.